CJ Cheiljedang Corporation (KRX:097950)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 3.61T |
| Revenue (ttm) | 27.34T |
| Net Income (ttm) | -571.46B |
| Shares Out | 16.02M |
| EPS (ttm) | -35,664.30 |
| PE Ratio | n/a |
| Forward PE | 9.90 |
| Dividend | 6,000.00 (2.56%) |
| Ex-Dividend Date | Feb 26, 2026 |
| Volume | 2,431 |
| Average Volume | 83,584 |
| Open | 235,500 |
| Previous Close | 233,000 |
| Day's Range | 233,000 - 235,500 |
| 52-Week Range | 186,100 - 270,000 |
| Beta | 0.13 |
| RSI | 54.97 |
| Earnings Date | May 12, 2026 |
About CJ Cheiljedang
CJ Cheiljedang Corporation engages in the food business in South Korea and internationally. It operates through Food, Biotechnology, Feed and Care, and Logistics segments. The company offers home meal replacement, meat/fishery processing, seasoning/sauce, sweetener/flour/oil, and seaweed/dessert/snack/beverage products. It also provides amino acid, green protein, enzyme, plant nutrition and health, and specialty solution; biopolymer solution; and polyhydroxyalkanoate products. In addition, the company offers taste and nutrition solutions. Furth... [Read more]
Financial Performance
Financial StatementsNews
CJ CheilJedang Corp (XKRX:097950) Q4 2025 Earnings Call Highlights: Navigating Growth and ...
CJ CheilJedang Corp (XKRX:097950) Q4 2025 Earnings Call Highlights: Navigating Growth and Challenges in Global Markets
Q4 2025 CJ CheilJedang Corp Earnings Call Transcript
Q4 2025 CJ CheilJedang Corp Earnings Call Transcript
CJ CheilJedang Corp (XKRX:097950) Q3 2025 Earnings Call Highlights: Navigating Market ...
CJ CheilJedang Corp (XKRX:097950) Q3 2025 Earnings Call Highlights: Navigating Market Challenges with Strategic Growth
Q3 2025 CJ CheilJedang Corp Earnings Call Transcript
Q3 2025 CJ CheilJedang Corp Earnings Call Transcript
CJ Cheiljedang Earnings Call Transcript: Q3 2025
Q3 2025 saw a 1.9% year-over-year revenue decline (excluding logistics) due to bio and feed & care weakness, while food business showed resilience and global expansion. Operating profit and net profit dropped sharply, with ongoing margin pressure in bio and cost headwinds in food.
CJ Cheiljedang Earnings Call Transcript: Q2 2025
Q2 2025 saw flat sales overall, with overseas food and bio growth offsetting domestic food weakness. Net profit rose 40% year-over-year, while operating profit declined due to higher costs and weak Korean demand. Q3 guidance projects low single-digit revenue growth and stable margins.
CJ Cheiljedang Earnings Call Transcript: Q1 2025
Q1 2025 saw overseas food sales growth and strong online expansion, but overall sales and OP declined due to bio and FNC setbacks and high raw material costs. Bio segment benefited from anti-dumping duties, while logistics and feed/care showed mixed results. Q2 sales growth is projected in the low to mid single digits.
CJ Cheiljedang Earnings Call Transcript: Q4 2024
Q4 operating profit rose year-over-year, led by BIO and Feed & Care, but net profit was negative due to asset impairments. Food and BIO segments saw growth, while U.S. food faced short-term supply disruptions. Dividend payout and CapEx guidance were raised for 2025.
CJ Cheiljedang Earnings Call Transcript: Q3 2024
Q3 2024 saw modest OP growth as global and bio segments offset declines in Korea. Online food sales surged, while bio and logistics units delivered strong profit gains. Q4 outlook is positive, with expected sales and OP margin improvements driven by new products and market expansion.
CJ CheilJedang Corp (XKRX:097950) Q2 2024 Earnings Call Transcript Highlights: Strong US Growth ...
CJ CheilJedang Corp (XKRX:097950) Q2 2024 Earnings Call Transcript Highlights: Strong US Growth and Bio Segment Performance Amid Domestic Challenges
CJ Cheiljedang Earnings Call Transcript: Q2 2024
Q2 2024 saw 14% OP growth, led by high-margin bio products and improved Feed and Care margins, despite a slight sales decline in food. U.S. and Europe drove global growth, while Korea faced weak consumer demand. Q3 is expected to see low single-digit sales growth and 6%-7% OP.